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AbstrACt
Introduction  National and international guidelines 
make recommendations for secondary prevention of 
stroke including the use of medications. A strategy 
which engages patients in a conversation to personalise 
evidence-based educational material (patient-centred 
educational exchange; PCEE) may empower patients to 
better manage their medications. 
Methods and analysis This protocol outlines a non-blinded 
randomised controlled trial. Consenting patients admitted 
with a diagnosis of stroke or transient ischaemic attack will 
be randomised 1:1 to receive either a PCEE composed of 
two sessions, one at the bedside before discharge and one 
by telephone at least 10 days after discharge from hospital 
in addition to usual care (intervention) or usual care alone 
(control). The primary aim of this study is to determine 
whether a PCEE improves adherence to antithrombotic, 
antihypertensive and lipid-lowering medications prescribed 
for secondary prevention of stroke over the 3 months 
after discharge, measured using prescription-refill data. 
Secondary aims include investigation of the impact of the 
PCEE on adherence over 12 months using prescription-
refill data, self-reported medication taking behaviour, self-
reported clinical outcomes (blood pressure, cholesterol, 
adverse medication events and readmission), quality of life, 
the cost utility of the intervention and changes in beliefs 
towards medicines and illness.
Ethics and dissemination Communication of the 
trial results will provide evidence to aid clinicians in 
conversations with patients about medication taking 
behaviour related to stroke prevention. The targeted 
audiences will be health practitioners and consumers 
interested in medication taking behaviour in chronic 
diseases and in particular those interested in secondary 
prevention of stroke. The trial has ethics approval from 
Metro South Human Research Ethics Committee (HREC/15/
QPAH/531) and The University of Queensland Institutional 
Human Research Ethics (2015001612).
trial registration number ACTRN12615000888561; Pre-
results.
IntroduCtIon  
Stroke is one of the leading causes of death 
worldwide.1 2 About a third of those who 
suffer from a stroke die within 28 days and 
a further third are left permanently disabled 
placing a burden on themselves, their family 
and the community.3 4 After an initial stroke 
the cumulative incidence of a subsequent 
stroke is about 30%, with the highest occur-
rence in the first 12 months (12%).5–7 In 
an individual experiencing a transient isch-
aemic attack (TIA) or a minor stroke (<3 
on the National Institutes of Health Stroke 
Scale8), the 30-day incidence of stroke is 
11%–15%.9 After either a stroke or TIA, 
International10–12 and Australian guidelines13 
recommend secondary prevention strategies. 
Recommendations include the use of anti-
thrombotic therapy, medications for blood 
pressure (BP) lowering and cholesterol-low-
ering medications. The high rate of recur-
rence in the first weeks and months of a minor 
stroke or TIA emphasises the importance of 
early initiation and subsequent persistence 
to secondary prevention medicines to reduce 
strengths and limitations of this study
 ► The design of randomising participants to the pa-
tient-centred educational exchange   will provide 
the opportunity to take into account other changes, 
which may occur across the time of the study.
 ► The use of questionnaires, validated as research 
tools, to elicit patient perceptions will be integrated 
with the approach used in ‘academic detailing’.
 ► The strength of the intervention is that it is under-
pinned by a combination of theories of behavioural 
change.
 ► This study links the use of both prescription refill 
data as an objective adherence measurement and 
patient self-reported adherence.
 ► As is common with many behavioural intervention 
studies, this study is not blinded once the participant 
has been allocated to either the intervention or con-
trol group, which may introduce bias to the study.
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the risk of subsequent stroke.9 Stroke survivors may not 
benefit due to poor adherence to the medications14–16 or 
the benefit may be offset by the occurrence of adverse 
drug events.17 Reports of patient adherence to secondary 
prevention medications vary widely ranging from 40%14 
to 86%15 and are influenced by the timing and method 
of measurement. There are many reasons reported 
for reduction in adherence including: lower income, 
multiple comorbidities, minor stroke or TIA,18 forgetful-
ness, trivialising stroke and low necessity beliefs in taking 
medications.19 
Educational interventions focused on improving 
patient use of medications for secondary prevention of 
stroke have shown impact on patients’ knowledge, but 
other outcome measures have had varied results.20–22 
Debate centres on whether a change in knowledge 
will result in a change of medicine-taking behaviour 
or whether alternative approaches such as addressing 
necessities and concerns about medication,23 agreeing 
goals or providing key messages about medication 
taking will be more effective in changing behaviour. 
Previously validated questionnaires have been used to 
identify patients’ perceptions of their illness,24 beliefs 
about medications25 and medication-taking behaviour,26 
and these have been used to provide a structure to 
encourage patient input into a personalised inter-
vention.27 Another approach to empower patients in 
medication-related self-management has incorporated 
‘academic detailing’28 29 also described as ‘educational 
visiting’.30 31 Academic detailing uses a social marketing 
framework, to encourage information exchange while 
delivering key messages in order to influence behaviour. 
The approach includes the following key features: iden-
tifying baseline knowledge and motivations for medi-
cation use, defining clear educational and behavioural 
objectives, establishing credibility, referring to author-
itative sources of information, and presenting both 
sides of controversial issues, stimulating participation in 
educational interactions, using concise graphical educa-
tional materials, highlighting and repeating the essen-
tial messages and providing positive reinforcement of 
improved practices in follow-up communication.28
Combining these two strategies, identifying patients 
perceptions’ and beliefs’ then using these to person-
alise educational messages and to engage patients in a 
conversation, may empower patients to better manage 
their medications. This approach will be referred to as 
a patient-centred educational exchange (PCEE). The 
PCEE has been tested for feasibility, and was found to be 
acceptable to the participants, manageable for the health-
care professional and the beliefs and perceptions elicited 
by the questionnaires were able to be used to personalise 
the conversation.32 A limitation of this feasibility study was 
that because the researcher delivered the intervention, 
the training requirements, use of resources and opinions 
of staff were not evaluated. The impact of the PCEE on 
patient self-management of stroke prevention medica-
tions has yet to be determined.
Aim
The primary aim of this study is to determine whether 
a PCEE improves adherence to antithrombotic, antihy-
pertensive and lipid-lowering medications prescribed for 
secondary prevention of stroke over the 3 months after 
discharge, measured using prescription refill data.
Secondary aims include: investigation of the impact of 
the PCEE on adherence over 12 months using prescrip-
tion refill data, self-reported medication-taking behaviour, 
self-reported clinical outcomes (BP, cholesterol, adverse 
medication events and readmission), quality of life, the 
cost utility of the intervention and changes in beliefs 
towards medicines and illness.
To address these aims, we will conduct a randomised 
controlled trial (RCT), with an intervention comprised 
of two PCEE sessions: one before discharge from hospital 
and one by telephone at least 10 days after discharge.
MEthods And AnAlysIs
This protocol was developed in accordance with the Stan-
dard Protocol Items: recommendations for intervention 
trials (SPIRIT) statement (see online supplementary file 
1. SPIRIT checklist).
study design
This study is a non-blinded RCT. Participants will be 
randomised 1:1 to either the intervention group (inter-
vention and usual care) or the control group (usual care).
setting
The setting will be the ‘Medical Stroke Unit’ (MSU) or 
the Medical Assessment and Planning Unit (MAPU), of 
an Australian tertiary referral hospital.
study population
Inclusion criteria
Participants recruited to this study must be aged 18 years 
or older, have been admitted to the MSU or the MAPU 
with a principal diagnosis of stroke or TIA, and are 
planned to be discharged to their home.
The participant should be expecting to manage their 
own medication after discharge home, have a docu-
mented Mental Status Questionnaire (MSQ)33 score of 
10/10 at the time of recruitment and be able to provide 
consent. The consent form requires the researcher to sign 
a declaration saying that they have given a verbal explana-
tion of the research project, its procedures and risks, and 
believe that the participant has understood that explana-
tion. This means the participant is unlikely to have severe 
problems with verbal communication.
Exclusion criteria
Those patients planned for discharge to a residential care 
facility (eg, a nursing or residential care home) where a 
staff member is responsible for the patients’ medication 
administration, those patients who have been planned for 
a rehabilitation period of greater than 1 month as they 
will be having weekly education sessions, those with an 
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MSQ <10, unable to complete the questionnaire (even) 
with assistance (this may be due to language difficulties 
or cognitive impairment) and those who do not provide 
consent. Those who are excluded will receive standard 
care, which includes education, without incurring any 
disadvantage.
Patient and public involvement
A feasibility study32 was conducted to inform the design 
of the PCEE used in this RCT. Of the 18 participants, 10 
completed an evaluation of the proposed intervention 
which resulted in changes to the final protocol. This 
included improved graphics to be used in this study, the 
use of mobile telephones with messaging to facilitate 
follow-up calls, and bridging sentences between ques-
tionnaires and the use of the infographic. With respect 
to the burden of the intervention, 7 of the 10 indicated 
that the session was not too long or too short and 9 of 10 
agreed that the materials helped them. The participants 
were invited to ask a questions and prompted to discuss 
previous experiences as part of the feasibility study, this 
has been included in the current protocol.
Patients and public were not involved in development 
of the research question or outcome measures, they will 
not be involved in the recruitment or ongoing conduct of 
the current study. The participants will be given contact 
details to request the results of the study.
recruitment
All admissions to MSU and MAPU will be screened using 
‘bed lists’ for 5 days of every week. Those admissions with 
a diagnosis of stroke or TIA will be further screened for 
a documented MSQ of 10/10 and plan for further reha-
bilitation or discharge to home. The researcher will then 
approach the potential participants on the ward to deter-
mine whether they are willing to participate in the study.
Allocation/randomisation
The allocation of participants to control or interven-
tion will be concealed until the participant has been 
consented to reduce allocation bias. After the participant 
has consented to the study, the research pharmacist will 
contact the clinical trials pharmacist, who is not involved 
in the study and who will identify the allocation, one to 
one, to either the intervention or control group. The 
allocation will be previously determined using a comput-
er-generated four block randomisation code using Sealed 
Envelope.34 The allocation will be concealed by placing 
the allocation in sealed opaque envelopes stored in the 
clinical trials office of the pharmacy department.
Once the participant is allocated, the researcher will 
no longer be blinded to participant’s allocation. The 
reason the researcher will no longer be blinded is that the 
researcher will conduct the intervention and follow-up 
calls.
Sample size
The primary outcome is adherence measured by the 
proportion of days covered (PDC) (defined as the days of 
medication supplies when the medications were collected 
divided by the days in the time interval) over the 3 months 
after discharge, using prescription refill data for three 
classes of medications (antithrombotic, antihypertensive 
and lipid-lowering medications).
The sample size calculation used the criterion for 
significance (alpha) set at 0.05 and the power (beta) at 
80%. It is proposed that the intervention will result in 
a 7% improvement in adherence compared with stan-
dard care. This difference of 7% was selected as reason-
able; because an effect of this magnitude has been 
shown with secondary prevention medications used for 
cardiovascular diseases35 36 and has been linked to a 
clinical difference.37 An effect size of 0.54 (0.07/0.13) 
was selected using results from a study conducted with 
participants discharged on similar medications after a 
diagnosis of acute coronary syndrome.36 A sample size 
of 55 in each arm is required for effect size of 0.54. We 
allowed for a slighter larger pooled SD of 0.15 (effect size 
0.7/0.15=0.47) requiring a sample size of n=73. Adher-
ence data are likely to be skewed38 and so will not fulfil 
the requirements for a parametric test. Lehmann and 
D'Abrera39 suggest the addition of 15% more participants 
(n=84) when planning to use non-parametric tests such 
as the Mann-Whitney U test. Assuming attrition rates of 
approximately 10%, we would need to enrol at least 92 
participants for each group; we propose to include 100 
participants in each arm. It is predicted that approxi-
mately two participants will be recruited per week, esti-
mating a 2-year recruitment period. The first participant 
was recruited on the 18 December 2015 and the study 
will be ongoing until April 2019.
Procedure
Both the intervention and control group will receive 
usual care. In addition to usual care participants in the 
intervention group will receive two sessions of a ‘PCEE’, 
one before discharge and one by telephone at least 10 
days after discharge. These sessions will be conducted 
by a clinical pharmacist who attends weekly multidisci-
plinary MSU meetings, has a postgraduate qualification 
in clinical pharmacy (MSc ClinPharm) and training in 
academic detailing. In this study, the intervention phar-
macist will also be collecting the study data.
Usual care
Usual care includes admission to a stroke-specific ward, 
multidisciplinary care by the stroke team, education 
using Stroke Foundation-Australia materials by the stroke 
nurse,40 clinical pharmacy services provided by the ward 
pharmacist and discharge advice provided by the medical 
staff. Usual care provided by the ward pharmacist includes 
medication history taking and reconciliation, medication 
review during the admission, discharge reconciliation, 
provision of a medication list41 and medication counsel-
ling at discharge.
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Control group
The control group will receive usual care as described 
above.
Intervention: PCEE
The intervention consists of two sessions, one which will 
take place at the patients’ bedside before the usual phar-
macist discharge counselling and the second which will 
be conducted over the telephone at least 10 days after 
discharge. These sessions are additional to and designed 
to integrate with usual care. The PCEE is structured with 
an introduction, conversation and conclusion.
The session begins with an ‘introduction’ phase estab-
lishing credibility ‘I am a pharmacist with an interest in 
patients taking medication to reduce the risk of stroke.’ 
Next, the clinical pharmacist will give the opportunity 
to the patient to ask a question. ‘What one thing would 
you most like to discuss about medications you have been 
prescribed since your stroke/TIA?’ There is an opportu-
nity to answer this question before moving on.
The session will then move into the ‘conversation’ 
using previously validated questionnaires to identify 
patients’ perceptions, beliefs and concerns about their 
stroke in general (using the Brief-Illness Perception 
Questionnaire (Brief-IPQ)24 and medications in partic-
ular (using the Beliefs about Medicine Questionnaire 
specific (BMQ-specific).25 There is also an opportunity 
for the patient to self-report their previous medication 
taking behaviour for the medications of interest (using 
the Medication Adherence Questionnaire (MAQ).26 The 
identified barriers and enablers will be used to person-
alise the conversation. A double-sided single page docu-
ment will be personalised and given to the participant 
(the detailing tool). The detailing tool contains an info-
graphic to help illustrate the discussion about the stroke 
prevention medications the patient has been prescribed 
on one side, and four a priori key messages on the 
other side (see online supplementary file 2. infographic 
example).
The four key messages are: ‘Know about your medi-
cations prescribed to reduce risk of stroke’, ‘Organise 
ongoing supply of your medications’, ‘Continue to take 
these medications as agreed with your doctors’ and 
‘Report any new symptoms or concerns to your doctor’.
In the final phase, ‘conclusion’, items identified to be 
discussed when the clinical pharmacist telephones the 
patient will be listed.
To provide an opportunity for ‘follow-up’ and rein-
forcement of key messages, the intervention is designed 
to include two sessions. The clinical pharmacist 
will arrange to telephone the participant at least 10 days 
after discharge to ask them the same questions and to talk 
about their medications.
It is hypothesised that patients in the intervention group 
will be influenced to organise ongoing supply of their 
medications and take their medications as prescribed. 
In addition, it is hoped that if they identify that they are 
experiencing unwanted effects from a medication(s), 
they will not keep taking medication(s) long term, rather 
discuss their concerns with their doctor.
outcomes
The primary outcome is adherence measured by the PDC 
over the 3 months after discharge, using prescription 
refill data (obtained from the Pharmaceutical Benefits 
Scheme; PBS) for the combination of up to three classes 
of medications (antithrombotic, antihypertensive and 
lipid-lowering medications) prescribed.
Secondary outcomes include:
 ► Adherence measured by the PDC over the 12 months 
after discharge, using prescription refill data for up to 
three classes of medications (antithrombotic, antihy-
pertensive and lipid-lowering medications).
 ► Self-reported medication adherence (measured using 
the MAQ), organising of ongoing medication supply, 
and medication-taking behaviour and communica-
tion to prescriber in response to perceived medica-
tion-related adverse events.
 ► Self-reported changes between baseline and 3 and 12 
months in perception to their illness (stroke) using 
Brief-IPQ and changes between baseline and 3 and 
12 months in beliefs about medications for stroke 
prevention using BMQ-specific.
 ► Clinical outcomes:
 – Medication-related adverse events (identified by 
self-report or hospital readmission).
 – Self-report of BP results.
 – Self-report of cholesterol level.
 – Readmission to hospital with stroke and/or myo-
cardial infarction (MI) (identified by self-report or 
hospital records).
 ► Changes from baseline to 3 and 12 months in self-re-
ported quality of life using the EuroQol 5 dimension, 
5 level quality of life tool (EQ-5D-5L).42 43
 ► Cost–utility analysis using a ratio of incremental cost 
(cost of the PCEE intervention compared with usual 
care) to incremental benefit (change in quality-ad-
justed life years (QALYs).44
The complex relationship between the interven-
tion described here and the measures of the impact we 
expect to make has been described by authors of previous 
studies.45 46 Table 1 categorises the study outcome meas-
ures by outcome type and who measures it. 
Behavioural measures
Behavioural measures look at things the participant has 
done. In this study visiting the doctor and having their 
medication dispensed is observer collected.47 48 Pharma-
ceutical claims data can provide an objective, non-invasive 
measure of adherence and has been used in many drug 
trials and in a number of studies similar to this one. A 
range of methods for use of claims data to measure medi-
cation possession ratios and PDC have been described to 
assess an individuals’ medication adherence.38 47–50
The PDC is defined as the days of medication supplies 
when the medications were collected divided by the days 
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in the time interval. This can be averaged over the total 
(eg, a 90-day interval), or to be more reflective of medi-
cation exposure, a shorter interval can be measured and 
added together (eg, in Australia most medications for 
chronic diseases are supplied at approximately 1-month 
intervals). The PDC calculated using multiple short inter-
vals49 50 can more accurately account for gaps in supply 
or extra medication supplies. The example shown in 
figure 1 adapted from Bijlsma et al49 and Bryson et al50 
shows how the adherence over three lots of 30-day inter-
vals can be calculated using the gaps in supply for three 
patients obtaining 30-day supplies. The calculation used 
is: Proportion of 90 days covered=(90 –total of days not 
covered in each 30-day interval)/90×100.
Patient 1 obtained medications on the day of discharge, 
30 days later and then had a gap of 5 days before the third 
supply. Patient 1 PDC=[(30+0)+(30+0)+(30−5)]/90×100
=94%.
Patient 2 obtained the first supply 5 days before 
discharge, these were not used until the day of discharge 
so although the second supply was obtained 10 days 
after the first supply, there was only a 5-day gap in supply 
for the patient. Five days of tablets remaining from 
the second supply were used in the third interval. The 
third supply was obtained after a 10-day gap. Patient 2 
PDC=[(30+5–5)+(30−5)+(30+5–10)]/90×100=89%.
Patient 3 obtained medications on the day of 
discharge, 20 days later and then had a gap of 
40 days before the third supply. Patient 3 PDC= 
[(30+0)+(30+10–10)+(30−30)]/90×100=67%.
In this study the days covered in each dispensing interval 
will be calculated for up to three different medications 
(antithrombotic, antihypertensive, lipid-lowering medi-
cation) dependant on the medication plan at discharge. 
These will then be expressed as a mean (across the up to 
three medications) percentage and analysed as a contin-
uous variable.
Self-reported behavioural measures in this study 
include self-report of medication adherence using the 
MAQ,26 organising an ongoing medication supply and 
action taken if they experience adverse effects from their 
medication. The MAQ is a well-validated scale, previously 
used in many clinical conditions.51
Affective cognitive outcomes
Affective cognitive outcomes include measures of what 
the participant knows and how they feel, these are usually 
self-reported.
In this study, the affective cognitive group includes 
metrics such as knowledge and understanding regarding 
Table 1 The proposed measures categorised by outcome type and who measures it
Behavioural outcomes
Affective–cognitive outcomes: (this 
includes knowledge, understanding, 
satisfaction) Health outcomes Economic outcomes
Patient 
self-
reported
Self report of adherence 
using MAQ
Participant ability to identify each 
medication of interest along, reason for 
use when answering the MAQ
Blood pressure,  
cholesterol levels
Self-report of organising 
medication supply
Participant knowing their: blood pressure, 
cholesterol level
Blood pressure, 
cholesterol levels
Self report of action if they 
experienced an ADE
Participant beliefs and perceptions using 
the BMQ-specific and brief-IPQ
Self reported quality of 
life EQ-5D-5L
Self reported quality of 
life EQ-5D-5L
Self reported ADE
Observer 
collected
Visit to doctor—Medicare 
data
Readmission/admission 
for ADE
Readmission/admission 
for ADE(s)
Prescription refills—
pharmaceutical benefits 
scheme data
Events-stroke, MI Events-stroke, MI
Time to conduct 
intervention
Adapted from Shay and Lafata.45
ADE, adverse drug event; BMQ specific, Beliefs about Medicine Questionnaire specific25; Brief-IPQ, brief Illness Perception 
Questionnaire24; EQ-5D-5L, Quality of Life Measure42; MAQ, Medication Adherence Questionnaire26; MI, myocardial infarction.
Figure 1 Examples of proportion of days covered calculated 
using multiple 30-day intervals.
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name, type and dose of medications, participants knowing 
their BP reading or cholesterol level, participants’ percep-
tions of their illness and beliefs about their medications. 
Participant perceptions of their stroke will be evalu-
ated using the adapted-Brief IPQ at baseline, 3 and 12 
months. Beliefs about antithrombotic, antihypertensive 
and lipid-lowering medications will be evaluated using 
the BMQ-specific at baseline, 3 months and 12 months. 
Changes in these may be able to be used to explain 
changes in other measures for example adherence.46
Health outcomes
In this study, we will evaluate patient self-reported clin-
ical measures (BP and Cholesterol), readmissions, subse-
quent stroke or MI, adverse drug reactions and quality of 
life.
Medication-related adverse events will be identified 
by patient self-report using probe questions adapted 
from a previously validated trigger tool52 at 3 months 
and 12 months for each medication class of interest. 
Medication-related adverse events will also be collected 
from any readmission notes at 3 months and 12 months 
postdischarge.
Quality of life will be measured using EQ-5D-5L42 
before discharge (baseline), 3 months and 12 months. 
This tool (EQ-5D-5L) has previously been used in stroke 
research.53
Economic outcomes
Economic outcomes will be determined from the health 
service perspective using an incremental cost-effective-
ness ratio (ICER). The ICER indicates the difference 
between the intervention and control cost (time and 
resources costed) per the difference in QALYs deter-
mined using the quality of life measure EQ-5D-5L. Time 
taken to deliver the PCEE sessions (intervention group 
only) will be recorded on the interview schedule at both 
the bedside (before discharge) and telephone follow-up 
(7–10 days post discharge) sessions and costed using stan-
dard pharmacist salary rates. Any impact of the interven-
tion on health resource use (eg, medication use, hospital 
readmissions) will be considered when estimating costs. 
Patient interview using EQ-5D-5L will be conducted 
before discharge (baseline), at 3 months and 12 months. 
Uncertainty in the estimated ICER will be evaluated using 
non-parametric bootstrapping techniques.
data collection
A schedule of assessments including the timing for data 
collection is shown in table 2. Data will be collected by 
the investigator prior to the patient’s discharge, at least 
10 days after discharge (intervention group only), at 3 
months and at 12 months.
Demographic data collected prior to the patients 
discharge include patient age, sex, stroke type, whether 
they have had a previous stroke, whether they live alone, 
cholesterol levels and BP on discharge. The demographic 
data are required to describe the population in the study 
and to ensure the intervention and usual care groups are 
comparable.
Participant self-reported data will be obtained by the 
researcher conducting telephone follow-up using the 
telephone numbers they provide during consent. If the 
participant does not answer the first call and has provided 
a mobile telephone number, the researcher will send a 
text message using the study mobile phone asking for a 
‘good time to talk’. The protocol allows for a total of three 
attempts to contact the participant for follow-up calls.
data management
Data will be entered electronically from the case record 
forms using a study number with no identifying informa-
tion into Microsoft Excel and SPSS Statistics V.25 both 
stored on a password-protected computer. In all reports 
from this research, information will be provided in such a 
way that the participant cannot be identified. Data entry 
and analyses will be performed using Microsoft Excel and 
SPSS Statistics V.25.
data analysis
An intention-to-treat analysis will be conducted. Results 
will be reported as numbers and percentages for cate-
gorical variables and means (SD) or medians (IQR) for 
continuous variables. Demographic data and baseline 
characteristics in the intervention and control groups will 
be compared using descriptive statistics. Outcomes and 
changes in outcomes (from baseline) will be compared at 
3 months and 12 months.
Adherence measured using the PDC from the prescrip-
tion refill data will be compared using the Mann-Whitney 
U two-sided test. Changes from baseline in quality of life, 
perceptions of illness and beliefs about medicines will be 
analysed using the Mann-Whitney U test. Adherence by 
self-report, medication-related adverse events and read-
missions will be analysed using the χ2 test.
Adverse event reporting and quality assurance
This study involves completing a questionnaire and 
discussing stroke medications through one face-to-face 
interview and three follow-up telephone calls for the 
intervention group. The control group will complete one 
face-to-face interview and two follow-up telephone calls. 
It is possible that during either the face-to-face interview 
or one of the telephone interviews, the participant iden-
tifies a medication-related issue. Although this is unlikely 
to be as a result of the study, the researcher may still have 
concerns over the patients’ safety. If the researcher has 
concerns requiring immediate intervention, the patients’ 
doctor will be contacted. In the case of the face-to-face 
interview in the hospital that will be a medical member of 
the treating team. In the case of the telephone interview 
that will be the patients’ general practitioner.
This is an RCT where data on adverse drug reactions 
and events including stroke and readmission will be 
collected. It is possible that differences can be deter-
mined between the two groups before the recruitment 
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period is complete. A data safety monitoring committee 
(consisting of an independent medical doctor—clinical 
pharmacologist and pharmacist—Drug Use Evaluation 
Pharmacist) has been established to analyse the adverse 
events every 6 months with responsibility to terminate 
recruitment into the study early if necessary.
This RCT will provide evidence about the effect of 
a PCEE on patient adherence, self-reported medica-
tion-taking behaviour, clinical outcomes, quality of life, 
changes in knowledge and beliefs towards medicines 
and illness. It is expected that communication of results 
will inform an evidence-based approach to communica-
tion with patients about medication-taking behaviour 
related to stroke prevention. Communication of results 
of this study will seek to impact on the practice of health 
practitioners and consumers interested in patient medi-
cine-taking behaviour and those interested in secondary 
prevention of stroke.
EthICs And dIssEMInAtIon
Participants will be provided with information about the 
study and asked if they consent to the study; ‘Participant 
information and consent form’ (see online supplemen-
tary file 3. Patient Information and Consent Form). To 
obtain consent for medication refill data from the PBS 
and occasions of service by visits to doctor data from 
Medicare, the patients will be given an extra consent 
Table 2 Schedule of enrolment, interventions and assessments for patient-centred educational exchange (PCEE) to improve 
patients’ self-management of medications after a stroke
Time point -t1
-t2 before 
discharge
t0 date of 
discharge
t1 
approximately 
10 days 
postdischarge
t2 
approximately 
3 months 
postdischarge
t3 
approximately 
12 months 
postdischarge
Procedure Detail Baseline
Postallocation
Intervention Intervention Evaluation Evaluation
Enrolment:
  Eligibility screen MSQ*=10 not 
for extended 
rehabilitation
X
  Informed consent X
  Randomisation X
Intervention:
  First session 
(PCEE)
Bedside interview 
time taken†
X
X
  Second session 
(PCEE)
10-day follow-up 
interview time taken†
X
X
Assessments:
  Brief-IPQ X X X X
  BMQ-specific X X X X
  MAQ X X X X
  EQ-5D-5L X X X
  BP, cholesterol X* X‡ X‡
  PBS/
Medicare claims 
data
X X
  Admissions X X
  Stroke, MI X X
  Self-report of 
ADRs and action if 
ADRs
X X
*These are standard care clinical tests performed as part of routine patient care.
†Time taken for PCEE.
‡Self reported by participants.
ADR, adverse drug event; BMQ specific, Beliefs about medicines Questionnaire25; BP, blood pressure; Brief IPQ, Brief Illness 
Perception Questionnaire24; EQ-5D-5L, Quality of Life Measure 42; MAQ, Medication Adherence Questionnaire26; MI, myocardial 
infarction; MSQ, Mental State Questionnaire33; PBS/Medicare claims data, Dispensing data obtained from the Australians 
Pharmaceutical Benefits Scheme.
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form as required by the Department of Human Services. 
This is also contained in the ‘Participant information 
and consent form’. The patient can choose not to supply 
the extra consent for access to PBS/Medicare data. The 
participant is free to withdraw from the study at any time.
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